Acne vulgaris. Acne vulgaris
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Age 12 to 25 years Mild to moderate acne vulgaris
Exclusion criteria
Exclusion criteria: Active cancer Immune system defect History of allergy Uncontrolled systemic disease Receiving topical anti-acne treatment 2 months before or during the study Systemic antibiotic treatment during the study Use of oral contraceptive pills (OCP) and spironolactone 30 days before or during the study History of treatment with systemic retinoids Having a skin disease that may interfere with diagnosis or evaluation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reducing the number of skin lesions. Timepoint: First visit before treatment, second, fourth and eighth weeks. Method of measurement: Skin lesion count.;Reducing the number of inflammatory skin lesions. Timepoint: First visit before treatment, second, fourth and eighth weeks. Method of measurement: Skin lesion count.;Reducing the number of total skin lesions. Timepoint: First visit before treatment, second, fourth and eighth weeks. Method of measurement: Skin lesion count.;Reducing the acne severity index. Timepoint: First visit before treatment, second, fourth and eighth weeks. Method of measurement: Acne severity index = papules + (2 × pustules) + (comedones /4). | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects such as redness, itching, burning, and inflammation. Timepoint: Second, fourth and eighth weeks. Method of measurement: Asking the patient or the patient's mother. | — |
Countries
Iran (Islamic Republic of)
Contacts
Mazandaran University of Medical Sciences